Skip to content
Acipimox
Acipimox is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target hydroxycarboxylic acid receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AD: Nicotinic acid and derivatives, lipid modifying, plain
— C10AD06: Acipimox
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11121—35
Metabolic syndromeD024821EFO_0000195E88.81—11—12
Type 1 diabetes mellitusD003922EFO_0001359E10——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_0002614—1——34
HypertriglyceridemiaD015228EFO_0004211—1——12
Heart failureD006333EFO_0003144I50—1——12
Abdominal obesityD056128HP_0001956—1———1
Feeding and eating disordersD001068F50—1———1
Bulimia nervosaD052018EFO_0005204F50.2—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1———12
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypopituitarismD007018EFO_0001380E23.0————22
Glucose metabolism disordersD044882————11
Endocrine system diseasesD004700EFO_0001379E34.9————11
Brain diseasesD001927HP_0001298G93.40————11
Pituitary diseasesD010900E23.7————11
MetabolismD008660GO_0008152————11
Dilated cardiomyopathyD002311EFO_0000407I42.0————11
Cardiovascular diseasesD002318EFO_0000319I98————11
HyperlipidemiasD006949EFO_0003774E78.5————11
Hiv infectionsD015658EFO_0000764B20————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameACIPIMOX
INNacipimox
Description
5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cnc(C(=O)O)c[n+]1[O-]
Identifiers
PDB—
CAS-ID51037-30-0
RxCUI16817
ChEMBL IDCHEMBL345714
ChEBI ID—
PubChem CID5310993
DrugBankDB09055
UNII IDK9AY9IR2SD (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HCAR2
HCAR2
Organism
Homo sapiens
Gene name
HCAR2
Gene synonyms
GPR109A, HCA2, HM74A, NIACR1
NCBI Gene ID
338442
Protein name
hydroxycarboxylic acid receptor 2
Protein synonyms
G protein-coupled receptor HM74a, G-protein coupled receptor 109A, G-protein coupled receptor HM74A, hydroxy-carboxylic acid receptor 2, Niacin receptor 1, Nicotinic acid receptor
Uniprot ID
Q8TDS4
Mouse ortholog
Hcar2 (80885)
hydroxycarboxylic acid receptor 2 (Q9EP66)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 732 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
143 adverse events reported
View more details